EMA/630441/2019

European Medicines Agency decision

P/0411/2019

of 4 December 2019

on the acceptance of a modification of an agreed paediatric investigation plan for fremanezumab (AJOVY), (EMEA-001877-PIP01-15-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0411/2019

of 4 December 2019

on the acceptance of a modification of an agreed paediatric investigation plan for fremanezumab (AJOVY), (EMEA-001877-PIP01-15-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/0308/2017 issued 31 October 2017,

Having regard to the application submitted by Teva GmbH on 15 July 2019 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 18 October 2019, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for fremanezumab (AJOVY), solution for injection, subcutaneous use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Teva GmbH, Graf-Arco-Str. 3, 89079 – Ulm, Germany.

EMA/PDCO/418108/2019
Amsterdam, 18 October 2019

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-001877-PIP01-15-M02

Scope of the application

Active substance(s):

Fremanezumab

Invented name:

AJOVY

Condition(s):

Prevention of migraine headaches

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Solution for injection

Route(s) of administration:

Subcutaneous use

Name/corporate name of the PIP applicant:

Teva GmbH

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Teva GmbH submitted to the European Medicines Agency on 15 July 2019 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0301/2016 issued on 4 November 2016 and the decision P/0308/2017 issued 31 October 2017.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 20 August 2019.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member does agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Prevention of migraine headaches

The waiver applies to:

- the paediatric population from birth to less than 6 years;
- solution for injection, subcutaneous use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit over existing treatments.

2. Paediatric investigation plan

2.1. Condition

Prevention of migraine headaches

2.1.1. Indication(s) targeted by the PIP

Prophylaxis of headache in children aged 6 to less than 18 years with episodic and chronic migraine

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Solution for injection

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	0	
Non-clinical studies	2	**Study 1** Reproductive toxicity and post-natal development study. **Study 2** Definitive juvenile toxicity study.
Clinical studies	4	**Study 3** Pharmacokinetic and safety study in paediatric patients from 6 to less than 12 years of age following a single subcutaneous dose of fremanezumab (TV48125-CNS-10141).

		Study 4 Efficacy and safety, placebo controlled study of fremanezumab in paediatric patients from 6 to less than 18 years of age with episodic migraine (EM) (TV48125-CNS-30083). **Study 5** Efficacy and safety, placebo controlled study of fremanezumab in paediatric patients from 6 to less than 18 years of age with Chronic Migraine (CM) (TV48125-CNS-30082). **Study 6** Long-term, safety, tolerability and efficacy open-label single arm study of fremanezumab in paediatric patients from 6 to less than 18 years of age with history of migraine (CM or EM) who participated to Study 4 and 5 (TV48125-CNS-30084).
Extrapolation, modelling and simulation studies	3	**Study 7** Modelling and simulation dose-finding study based on a one-compartment model with allometric weight scaling with data from adult healthy volunteers and patients with EM and CM (CP-18-03). **Study 8** Modelling and simulation dose-finding study based on a two-compartment model with allometric weight scaling with data from paediatric pharmacokinetic study 3 (CP-18-05). **Study 9** Modelling and simulation inferential study including a comprehensive evaluation of the effect of covariates on PK and exposure-response parameters pooling all available paediatric and adult data.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By November 2024
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Prevention of migraine headaches

Authorised indication(s):

- AJOVY is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.

Authorised pharmaceutical form(s):

Solution for injection

Authorised route(s) of administration:

Injection